VIRADAY combines three active antiretroviral agents acting at different stages of the HIV lifecycle. Emtricitabine and tenofovir inhibit reverse transcriptase activity, while efavirenz targets non-nucleoside reverse transcriptase. Together, they block viral replication and prevent disease progression.
Recommended for:
Adults and adolescents (≥40 kg) with confirmed HIV-1 infection
First-line antiretroviral therapy
Once-daily dosing to enhance treatment adherence
Patients under medical supervision with comorbidities
Combination therapy for HIV-1 infection in adults and adolescents weighing ≥40 kg
VIRADAY should be taken orally once daily, preferably at bedtime to minimise CNS-related side effects. It is recommended to take the medicine on an empty stomach or at least 2 hours after a meal. Strict adherence to the prescribed schedule is essential.
Contraindications:
Hypersensitivity to any active ingredient
Severe hepatic impairment
Concurrent use of medications that strongly affect CYP3A enzymes
Side Effects:
Dizziness, insomnia, anxiety
Fatigue
Liver enzyme abnormalities
Skin rash
Altered lipid and creatinine levels
